Collaboration combines Lunit’s AI expertise with Agilent’s diagnostic leadership to revolutionize biomarker testing & enhance precision medicine capabilities
Lunit, a leading provider of artificial intelligence solutions for cancer diagnostics and therapeutics, and Agilent Technologies Inc., a global leader in life sciences, diagnostics, and applied chemical markets, have announced a nonexclusive collaboration to develop AI-based companion diagnostic (CDx) solutions. The partnership aims to integrate Lunit’s advanced AI technology with Agilent’s expertise in tissue-based diagnostics to address the growing demand for sophisticated biomarker assays in drug development.
Through this collaboration, the companies will co-develop AI-powered companion diagnostic tools designed to enhance diagnostic precision and improve the assessment of therapeutic efficacy. The initial efforts will focus on combining Lunit’s AI algorithms with Agilent’s cutting-edge assays to analyze biomarkers that are critical to the development of next-generation pharmaceutical therapies.
The joint solutions are expected to support pharmaceutical companies in the creation of companion diagnostic products, improving the accuracy of biomarker testing and enabling more personalized treatment strategies for patients.
Also Read: LabConnect & OmniScience launch agentic AI for trial data
“Biomarker testing is at the heart of precision oncology, but today it is still largely dependent on manual interpretation,” said Brandon Suh, CEO of Lunit. “By combining Agilent’s global leadership in tissue-based diagnostics with Lunit’s proven AI algorithms, we can help pharma partners bring biomarker-driven therapies to market faster and with greater confidence – ultimately ensuring patients receive the right treatment at the right time.”
“Agilent is committed to bringing cutting-edge diagnostic solutions to our pharmaceutical partners and ultimately to patients, and this collaboration with Lunit further strengthens our ability to offer the most advanced companion diagnostic solutions available today,” said Nina Green, vice-president and general manager of Agilent’s Clinical Diagnostics Division at Agilent. “Through this collaboration with Lunit, we aim to deliver next-generation diagnostic tools that enable the advancement of precision medicine worldwide.”
The partnership will initially concentrate on co-developing AI-enhanced assays for research and clinical trial applications. This strategic collaboration represents a significant milestone for both companies, highlighting their commitment to redefining the role of artificial intelligence in precision oncology and translational medicine.
